Literature DB >> 3649919

[Antibiotic resistance and serotypes of Streptococcus pneumoniae in Zurich (1984-1985)].

J Wüst, F H Kayser, G Morenzoni.   

Abstract

We have investigated the serotypes and sensitivity of 133 pneumococci against 11 antimicrobial agents in the agar dilution test. The strains had been isolated from clinical specimens sent to the Department of Medical Microbiology of the University of Zurich during 1984 and 1985. - Three strains (2.3%) had reduced sensitivity to penicillin G. 23 strains (17.3%) showed resistance or reduced susceptibility to tetracycline, one strain each (0.8%) to amoxycillin and cefaclor, and two strains each (1.5%) to erythromycin and sulfamethoxazole/trimethoprim. All pneumococcal strains investigated were susceptible to ceftazidime, ceftriaxone, chloramphenicol, vancomycin and ciprofloxacin. In view of this situation, routine testing of all clinically significant pneumococci is to be recommended. However, in the agar diffusion test the use of a penicillin G disk is unreliable and may give results with false sensitivity. Therefore, the susceptibility test should be performed with a disk containing oxacillin. - The prevalent capsular serotypes were - in descending order - types 3, 6, 23, 19, 14, 7, 8, 9, 1, and 17. 90.2% of the isolated pneumococci belonged to serotypes which are contained in the new vaccine "Pneumovax-23".

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3649919

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  3 in total

1.  Streptococcus pneumoniae as an agent of mastitis.

Authors:  J Wüst; M Rutsch; S Stocker
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

Review 2.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

3.  Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients.

Authors:  M Opravil; W Fierz; L Matter; J Blaser; R Lüthy
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.